AACR: Copanlisib + Rituximab Slows Relapsed Indolent Lymphoma
Significant reduction found in risk for disease progression/death for C+R versus placebo and rituximab
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.